Drug development effortsare focused on targeting various aspectsof AD pathology, including reducing β-amyloid production oraggregation, inhibiting tau protein accumulation, modulating neuroinflammation,and promoting synaptic function and neuronal survival. This evidence concerns the gene MAPT and Alzheimer disease.